Michael Meshad, MD
Hematology & Oncology · Mobile, ALNPI 1538112701
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.8% of the total across 785 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 11.8% — the pattern of someone who eats at a lot of different presentations.
Across 785 payments — averaging $18.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Astellas Pharma US Inc$1K
- Merck$830
- E.r. Squibb & Sons, L.L.C.$689
- Pfizer$649
- AstraZeneca$621
- plus $9K from 54 others
Across 1,627 payments — averaging $3263.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$1M
- Eli Lilly$869K
- Amgen$534K
- AstraZeneca$493K
- Genentech, Inc.$481K
- Merck$440K
- plus $1.5M from 22 others
What the payments were for
- Food & beverage$13,55395%
- Education$7445%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$14,297 in reported general payments places this provider in the 65th percentile of 177 hematology & oncology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 54 | $735,896 |
| CalquenceAcalabrutinib Maleate | 36 | $455,199 |
| ImbruvicaIbrutinib | 27 | $428,906 |
| KisqaliRibociclib Succinate | 22 | $378,642 |
| Lenalidomide | 20 | $269,919 |
| TagrissoOsimertinib Mesylate | 12 | $197,251 |
| BesremiRopeginterferon Alfa-2b-Njft | 12 | $189,308 |
| VerzenioAbemaciclib | 13 | $188,258 |
| Abiraterone Acetate | 53 | $157,359 |
| ArimidexAnastrozole | 12 | $18,690 |
| Letrozole | 214 | $4,601 |
| Tamoxifen Citrate | 33 | $1,423 |
| Anastrozole | 89 | $1,387 |
| Imatinib Mesylate | 18 | $1,369 |
| Dexamethasone | 39 | $894 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $134 | $735,89654 claims |
| AstraZenecaCalquence, Tagrisso | $621 | $652,44948 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $90 | $428,90627 claims |
| NovartisKisqali | $1,694 | $378,64222 claims |
| Lilly USA, LLCVerzenio, Olanzapine | $226 | $188,36827 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $36 | $157,35953 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 177 hematology & oncology providers in Alabama.
Other hematology & oncology in Mobile
- Anita MazloomMobile$20K
- Sherri ArledgeMobile$19K
- Daniel CameronMobile$17K
- Jose Galeas SorianoMobile$17K
- Amitkumar MehtaBirmingham$683K
- Pankit VachhaniBirmingham$545K
- Luciano CostaBirmingham$409K
- Khaleel AshrafBirmingham$379K
- Michael BirrerBirmingham$302K
- Rudolph NavariBirmingham$254K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.